Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alexis Onimus"'
Autor:
Alycia, Gardner, Álvaro, de Mingo Pulido, Kay, Hänggi, Sarah, Bazargan, Alexis, Onimus, Agnieszka, Kasprzak, Jose R, Conejo-Garcia, Katarzyna A, Rejniak, Brian, Ruffell
Publikováno v:
Journal for Immunotherapy of Cancer
Background T cell immunoglobulin and mucin domain containing−3 (TIM-3) blocking antibodies are currently being evaluated in clinical trials for solid and hematological malignancies. Despite its identification on T cells, TIM-3 is predominantly expr
Autor:
Alycia Gardner, Álvaro de Mingo Pulido, Kay Hänggi, Sarah Bazargan, Alexis Onimus, Agnieszka Kasprzak, Jose R Conejo-Garcia, Katarzyna A Rejniak, Brian Ruffell
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e003571
BackgroundT cell immunoglobulin and mucin domain containing−3 (TIM-3) blocking antibodies are currently being evaluated in clinical trials for solid and hematological malignancies. Despite its identification on T cells, TIM-3 is predominantly expre
Autor:
Olabisi Osunmakinde, Daiana Pamela Celias, Kay Hänggi, Alexis Onimus, Eslam Mohamed, Bruna Batista-Bittencourt, Xiaoqing Yu, Alycia Gardner, Álvaro de Mingo Pulido, Vincent C. Luca, Hatem Soliman, Tsuneyasu Kaisho, Kristen McEachern, Jie Li, Reymi Peña, Jimena Trillo-Tinoco, Brian Ruffell, Paulo C. Rodriguez, Johanna Kaufmann
Publikováno v:
de Mingo Pulido, Á, Hänggi, K, Celias, D P, Gardner, A, Li, J, Batista-Bittencourt, B, Mohamed, E, Trillo-Tinoco, J, Osunmakinde, O, Peña, R, Onimus, A, Kaisho, T, Kaufmann, J, McEachern, K, Soliman, H, Luca, V C, Rodriguez, P C, Yu, X & Ruffell, B 2021, ' The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake ', Immunity, vol. 54, no. 6, pp. 1154-1167 . https://doi.org/10.1016/j.immuni.2021.04.019
Immunity
Immunity
Blockade of the inhibitory receptor TIM-3 shows efficacy in cancer immunotherapy clinical trials. TIM-3 inhibits production of the chemokine CXCL9 by XCR1+ classical dendritic cells (cDC1), thereby limiting antitumor immunity in mammary carcinomas. W